Publications by authors named "Josep Tabernero"

100Publications

Incorporating traditional and emerging biomarkers in the clinical management of metastatic colorectal cancer: an update.

Expert Rev Mol Diagn 2020 Jul 22;20(7):653-664. Epub 2020 Jun 22.

Department of Medical Oncology, Vall d'Hebron University Hospital , Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14737159.2020.1782194DOI Listing
July 2020

Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer. Reply.

N Engl J Med 2020 02;382(9):877-878

Vall d'Hebron Institute of Oncology, Barcelona, Spain

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMc1915676DOI Listing
February 2020

Back-to-back discovery, co-precision, and prevention.

Eur Heart J Qual Care Clin Outcomes 2020 Apr;6(2):98-99

Medical Oncology Department, Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), P. Vall d'Hebron 119-129, 08035 Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/ehjqcco/qcz064DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7132911PMC
April 2020

Impact of Prior Bevacizumab Treatment on VEGF-A and PlGF Levels and Outcome Following Second-Line Aflibercept Treatment: Biomarker Analysis of the VELOUR Trial.

Clin Cancer Res 2020 Feb 14;26(3):717-725. Epub 2019 Nov 14.

Vall d'Hebron University Hospital and Institute of Oncology (VHIO), IOB-Quiron, UVic, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-19-1985DOI Listing
February 2020

The role of PIGF blockade in the treatment of colorectal cancer: overcoming the pitfalls.

Expert Opin Biol Ther 2020 Jan 16;20(1):15-22. Epub 2019 Oct 16.

Vall d´Hebron University Hospital (HUVH) and Vall d'Hebron Institute of Oncology (VHIO), Universitat Autònoma de Barcelona, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14712598.2020.1677603DOI Listing
January 2020

Encorafenib, Binimetinib, and Cetuximab in V600E-Mutated Colorectal Cancer.

N Engl J Med 2019 10 30;381(17):1632-1643. Epub 2019 Sep 30.

From the University of Texas M.D. Anderson Cancer Center, Houston (S.K., V.M.); West Cancer Center and Research Institute, OneOncology, Germantown, TN (A. Grothey); Memorial Sloan Kettering Cancer Center, New York (R.Y., A.K.); University Hospital Gasthuisberg and University of Leuven, Leuven, Belgium (E.V.C., J. Dekervel); the Peter MacCallum Cancer Centre, Melbourne, VIC, Australia (J. Desai, C.G.); National Cancer Center Hospital East, Kashiwa, Japan (T.Y.); Hammersmith Hospital, Division of Cancer, Imperial College London (H.W.), and the Sarah Cannon Research Institute and University College London Cancer Institute (H.-T.A.), London, and the Christie NHS Foundation Trust/National Institute for Health Research Manchester Biomedical Research Centre, Manchester (M.B.) - all in the United Kingdom; the University of Campania Luigi Vanvitelli, Naples (F.C.), and Istituto Oncologico Veneto, Istituto di Ricovero e Cura a Carattere Scientifico, Padua (F.L., S.L.) - both in Italy; Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea (Y.S.H., T.-W.K.); the Netherlands Cancer Institute, Amsterdam (N.S., J.H.M.S.); Oslo University Hospital, Oslo (T.K.G.); Hospital Gregorio Marañón, Madrid (P.G.-A., A.C.F.), and Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology, UVic, IOB-Quiron, Barcelona (E.E., J.T.) - both in Spain; Odense University Hospital, Odense, Denmark (P.P., L.S.T.); Pavlov First St. Petersburg State Medical University, St. Petersburg, Russia (S.O.); and Array BioPharma, Boulder, CO (A. Gollerkeri, C.K., K.M., M.P., J.C.-B., L.A., V.S.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1908075DOI Listing
October 2019

How I treat gastric adenocarcinoma.

ESMO Open 2019 5;4(Suppl 2):e000521. Epub 2019 Jul 5.

Medical Oncology, VHIO (Vall d'Hebron Institute of Oncology), University Hospital Vall d'Hebron, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/esmoopen-2019-000521DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6615878PMC
July 2019

Shortages of inexpensive essential medicines.

Lancet Oncol 2019 05 18;20(5):e224-e225. Epub 2019 Apr 18.

ESMO President, Medical Oncology Department, Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(19)30248-7DOI Listing
May 2019

Knowledge and use of biosimilars in oncology: a survey by the European Society for Medical Oncology.

ESMO Open 2019 6;4(2):e000460. Epub 2019 Mar 6.

Department of Medical Oncology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/esmoopen-2018-000460DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6435239PMC
March 2019

Two-way traffic: aligning expectations with current realities in oncology. Mid-term ESMO Presidency considerations.

Authors:
Josep Tabernero

ESMO Open 2019 31;4(1):e000494. Epub 2019 Jan 31.

Vall d'Hebron University Hospital and Institute of Oncology (VHIO), Universitat Autònoma de Barcelona, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/esmoopen-2019-000494DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6435243PMC
January 2019

ESMO-MCBS: setting the record straight.

Lancet Oncol 2019 04;20(4):e192

European Society for Medical Oncology-Magnitude of Clinical Benefit Scale Working Group, Lugano, Switzerland; Department of Medical Oncology, University Medical Center Groningen, University of Groningen, Groningen, Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(19)30174-3DOI Listing
April 2019

Triple-drug chemotherapy regimens in combination with an anti-EGFR agent in metastatic colorectal cancer - prospects from phase II clinical trials.

Expert Opin Investig Drugs 2019 05 20;28(5):463-471. Epub 2019 Apr 20.

a Department of Medical Oncology , Vall D'Hebron University Hospital Barcelona/Universitat Autònoma de Barcelona , Barcelona , Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/13543784.2019.1599860DOI Listing
May 2019

New clinical trial designs in the era of precision medicine.

Mol Oncol 2019 03 22;13(3):549-557. Epub 2019 Feb 22.

Medical Oncology Department, Vall d'Hebron University Hospital and Institute of Oncology (VHIO), Universitat Autònoma de Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/1878-0261.12465DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6396357PMC
March 2019

All change: closing the gender gap in oncology.

Authors:
Josep Tabernero

ESMO Open 2018 15;3(7):e000448. Epub 2018 Nov 15.

ESMO President 2018-2019, Medical Oncology Department, Vall d'Hebron University Hospital and Institute of Oncology, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://esmoopen.bmj.com/lookup/doi/10.1136/esmoopen-2018-000
Publisher Site
http://dx.doi.org/10.1136/esmoopen-2018-000448DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6242021PMC
November 2018

Biosimilars in oncology.

Authors:
Josep Tabernero

ESMO Open 2018 24;3(6):e000456. Epub 2018 Oct 24.

Universitat Autònoma de Barcelona, Vall d'Hebron University Hospital and Institute of Oncology (VHIO), Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/esmoopen-2018-000456DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6215690PMC
October 2018

Preparing for the incoming wave of biosimilars in oncology.

ESMO Open 2018 5;3(6):e000420. Epub 2018 Sep 5.

Vall d'Hebron University Hospital and Institute of Oncology (VHIO), Universitat Autònoma de Barcelona, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/esmoopen-2018-000420DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6144900PMC
September 2018

Molecular Subtypes and the Evolution of Treatment Decisions in Metastatic Colorectal Cancer.

Am Soc Clin Oncol Educ Book 2018 May;38:231-238

From the Oncology Data Science Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain; Sage Bionetworks, Fred Hutchinson Cancer Research Center, Seattle, WA; Department of Medical Oncology, Catalan Institute of Oncology, Oncobell Program, L'Hospitalet de Llobregat, CIBERONC, Barcelona, Spain; Medical Oncology Department, Vall d'Hebron University Hospital and Institute of Oncology, Universitat Autònoma de Barcelona, CIBERONC, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/EDBK_200929
Publisher Site
http://dx.doi.org/10.1200/EDBK_200929DOI Listing
May 2018

The safety of ramucirumab for the treatment of colorectal cancer.

Expert Opin Drug Saf 2018 Sep 16;17(9):945-951. Epub 2018 Aug 16.

c Department of Medical Oncology , Vall d'Hebron Institute of Oncology (VHIO) , Barcelona , Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14740338.2018.1506762DOI Listing
September 2018

Effect of Primary Tumor Location on Second- or Later-line Treatment Outcomes in Patients With RAS Wild-type Metastatic Colorectal Cancer and All Treatment Lines in Patients With RAS Mutations in Four Randomized Panitumumab Studies.

Clin Colorectal Cancer 2018 09 8;17(3):170-178.e3. Epub 2018 Mar 8.

Center for Oncological Research, University of Antwerp, Wilrijk, Belgium; Department of Oncology, Antwerp University Hospital, Edegem, Belgium. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clcc.2018.03.005DOI Listing
September 2018

Cancer Genome Interpreter annotates the biological and clinical relevance of tumor alterations.

Genome Med 2018 03 28;10(1):25. Epub 2018 Mar 28.

Research Program on Biomedical Informatics (GRIB), IMIM Hospital del Mar Medical, Research Institute and Pompeu Fabra University, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13073-018-0531-8DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5875005PMC
March 2018

RE: Magnitude of Clinical Benefit of Cancer Drugs Approved by the US Food and Drug Administration.

J Natl Cancer Inst 2018 10;110(10):1142-1143

Department of Medical Oncology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnci/djy029DOI Listing
October 2018

Phosphatidylinositol 3-Kinase α-Selective Inhibition With Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the First-in-Human Study.

J Clin Oncol 2018 05 5;36(13):1291-1299. Epub 2018 Feb 5.

Dejan Juric, Massachusetts General Hospital Cancer Center, Boston; Alan Huang, Novartis Institutes for BioMedical Research, Cambridge, MA; Jordi Rodon and Josep Tabernero, Vall d'Hebron University Hospital and Institute of Oncology, Universitat Autònoma de Barcelona; Marta Gil-Martin, Catalan Institute of Oncology - Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Spain; Filip Janku, The University of Texas MD Anderson Cancer Center, Houston, TX; Howard A. Burris, Sarah Cannon Research Institute and Tennessee Oncology; Jordan Berlin, Vanderbilt-Ingram Cancer Center, Nashville, TN; Jan H.M. Schellens, Netherlands Cancer Institute, Amsterdam, the Netherlands; Mark R. Middleton, National Institute for Health Research, Oxford Biomedical Research Centre, Churchill Hospital, Oxford, United Kingdom; Martin Schuler, West German Cancer Center, University Duisburg-Essen, and German Cancer Consortium, Partner Site University Hospital Essen, Essen; Ruth Seggewiss-Bernhardt, Comprehensive Cancer Center Mainfranken, University Hospital Würzburg, Würzburg, Germany; Hope S. Rugo, University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; Douglas Bootle, David Demanse, Lars Blumenstein, and Cornelia Quadt, Novartis Pharma AG, Basel, Switzerland; Christina Coughlin, Novartis Pharmaceuticals Corporation, East Hanover, NJ; and José Baselga, Memorial Sloan Kettering Cancer Center, New York, NY.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2017.72.7107
Publisher Site
http://dx.doi.org/10.1200/JCO.2017.72.7107DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5920739PMC
May 2018

Immune-Modified Response Evaluation Criteria In Solid Tumors (imRECIST): Refining Guidelines to Assess the Clinical Benefit of Cancer Immunotherapy.

J Clin Oncol 2018 03 17;36(9):850-858. Epub 2018 Jan 17.

F. Stephen Hodi and Mizuki Nishino, Dana-Farber Cancer Institute, Boston, MA; Marcus Ballinger, Benjamin Lyons, Chris McKenna, Ina Rhee, Gregg Fine, Nathan Winslow, and Daniel S. Chen, Genentech, South San Francisco, CA; Jean-Charles Soria, AstraZeneca, Gaithersburg, MD; Josep Tabernero, Universitat Autònoma de Barcelona, Barcelona, Spain; Thomas Powles, Queen Mary University of London, London, United Kingdom; David Smith, Compass Oncology, Vancouver, WA; Axel Hoos, GlaxoSmithKline, Collegeville, PA; Ulrich Beyer, Roche Innovation Center, Basel, Switzerland; and Jedd D. Wolchok, Memorial Sloan Kettering Cancer Center, New York, NY.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.75.1644DOI Listing
March 2018

The Cancer Moonshot from a European perspective.

Lancet Oncol 2017 11 31;18(11):e626. Epub 2017 Oct 31.

Vall d'Hebron University Hospital and Institute of Oncology (VHIO), Universitat Autànoma de Barcelona, CIBERONC, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(17)30798-2DOI Listing
November 2017

Reply to M. Mo et al.

J Clin Oncol 2018 01 21;36(3):303. Epub 2017 Nov 21.

Manish A. Shah, Meyer Cancer Center at Weill Cornell Medical College, Medical Oncology/Solid Tumor Program, New York, NY; Luis A. Herráaez-Baranda, F. Hoffmann-La Roche Ltd, Basel, Switzerland; Amit Garg, Genentech, South San Francisco, CA; and Josep Tabernero, Vall d'Hebron University Hospital and Institute of Oncology (VHIO), Universitat Autònoma de Barcelona, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.75.2758DOI Listing
January 2018